![Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.](https://oncodaily.com/pub/uploads/2023/10/328BCA73-4AB2-4D88-BFFC-DEFF5D67DE5D-e1697931433507-1280x894.jpeg)
Photo taken from Jose Fernando Moura/Twitter
Oct 21, 2023, 19:37
Jose Fernando Moura: Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line.
Jose Fernando Moura, Oncologist and Principal Investigator in Solid Tumors at Real Hospital Portuguese and IMIP, shared on X/Twitter from ESMO23:
“One more for the team! Phase 2 PERLA trial shows a new option in same setting NSCLC 1st line similar activity.”
Source: Jose Fernando Moura/Twitter.